My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
November 2014
Patient Care and Science
FDA Approves First Combination Pill for HCV
In early October, the Food and Drug Administration (FDA) approved a combination ledipasvir-sofosbuvir pill (Harvoni) to treat chronic hepatitis C virus infection. The pill is the first combination pill approved to treat chronic HCV genotype 1 infection and the first approved regimen that does not require administration with interferon or ribavirin.

IDSA offers two email services to help members stay informed of new drug approvals and similar updates from FDA and the Centers for Disease Control and Prevention (CDC). Content includes a range of topics, including drug warnings, recalls, and outbreak investigations. Recent alerts have included:


IDSA members can sign up for these services online. (To subscribe, check the appropriate boxes to receive CDC’s Health Alert Network [HAN] messages and/or alerts from FDA, and provide your email address and name where indicated.)

Is Your Facility Experiencing Antibiotic Shortages?

IDSA members are urged to report drug shortages directly to FDA and to copy IDSA staff at schang@idsociety.org.



< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
Now Available: Updated Guideline for Kidney Disease in HIV Patients
FDA Approves First Combination Pill for HCV
EIN Update: Tracking the Enterovirus D68 Outbreak
Clinical Practice Management
HIV Provider Resources: Outpatient Billing and Coding; ACOs and HIV Care
Policy and Advocacy
IDSA Testifies Before Congress on Antimicrobial Resistance
IDSA Urges Boost in Funding for Public Health Agencies in FY 2016 Budget
Society Calls for More Funding of ID Comparative Effectiveness Research
Global ID
On the Frontlines of the HIV/TB Response in Africa: Impacts and Gaps
Live from Cape Town and Barcelona: Biomedical HIV Prevention and the Fight Against TB
You and Your Colleagues
Members on the Move
New Members
Education and Resources
HIV Minority Clinical Fellowship Program: December 12 Application Deadline
Top Stories
From the President
The State of the Society: Reports from IDWeek 2014 Business Meeting
IDWeek 2014: Post Meeting Resources
Congratulations to the 2014 Society Award Winners!
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.